HER-2 mAbs, combined with chemotherapy or ADC, are preferred treatments for advanced breast cancer with HER2 expression/amplification, and PD-L1 inhibitors coupled with chemotherapy are suitable for advanced TNBC with PD-L1 expression. Here, ERBB2 is linked to breast cancer.